Meeting
2016 Gastrointestinal Cancers Symposium
Pembrolizumab (MK-3475) plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer: Preliminary safety data from KEYNOTE-059.
Authors
Charles S. Fuchs
Dana-Farber Cancer Institute, Boston, MA
Charles S. Fuchs , Atsushi Ohtsu , Josep Tabernero , Eric Van Cutsem , Jiang Dian Wang , Baohoang Lam , Minori Koshiji , Yung-Jue Bang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02335411
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 161)
DOI
10.1200/jco.2016.34.4_suppl.161
Abstract #
161
Poster Bd #
N9
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Preliminary safety data from KEYNOTE-059: pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer.
First Author: Charles S. Fuchs
Poster
2017 ASCO Annual Meeting
KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.
First Author: Yung-Jue Bang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results.
First Author: Yelena Y. Janjigian
Poster
2014 Gastrointestinal Cancers Symposium
A phase 2 study of trastuzumab in combination with S-1 and cisplatin in first-line human epidermal growth factor receptor (HER)-2-positive advanced gastric cancer.
First Author: Su Pin Choo